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Introduction
Neurofibromatosis type 1 (NF1, formerly known as von Reckling-
hausen disease) is an autosomal dominant genetic disorder. The 
prevalence of NF1 is approximately 1 in 3,500 births, regardless 
of sex and race (1–3). The common clinical presentations of NF1 
include neurofibromas, café-au-lait macules on the skin, freckles 
under the armpits or in the groin areas, Lisch nodules in the eyes, 
optic gliomas, scoliosis, and bone enlargement or malformation. 
Homozygous loss of NF1 caused by NF1 loss of heterozygosity can 
give rise to multiple types of neoplasms, and neurofibroma is the 
most common among them (2–7).
Neurofibroma is a nerve sheath tumor developing in the 
peripheral nervous system that can present in different distinct 
forms. However, for simplicity, most clinicians divide neurofibro-
mas into (a) cutaneous neurofibromas, which grow along cutane-
ous nerve twigs as numerous tumor nodules on the skin, and (b) 
plexiform neurofibromas, which develop along an internal nerve 
plexus. Plexiform neurofibromas continue to grow throughout life 
and there is a 10% lifetime risk for them to transform into malig-
nant peripheral nerve sheath tumors (8), life-threatening malig-
nancies. Current clinical treatment options for neurofibromas are 
limited to surgical resection, although pharmacological inhibition 
of MEK has recently shown success in an experimental animal 
model (9) and in the early phase of a clinical trial (10).
Neurofibromas are heterogeneous tumors comprised of neo-
plastic Schwann cells and nonneoplastic fibroblasts, vascular 
endothelial cells, and mast cells, as well as dense collagen. The 
presence of mast cell infiltration can be frequently observed in 
neurofibromas (11–14); however, it is not common in other types of 
neoplasms. The neurofibroma-associated mast cells appear to be 
at activated status, as levels of local histamine content (13) and cir-
culating serum IgE are high (15). This unique characteristic feature 
has made mast cells a target of interest in neurofibroma research. 
Efforts have been made to understand the role of mast cells in the 
neurofibroma tumor microenvironment, and most importantly, to 
determine whether mast cell metabolism could be a viable thera-
peutic target against neurofibromas (6, 16, 17).
Mast cells are immune effector cells that feature a high con-
tent of secretory granules containing multiple types of immuno-
modulatory molecules, such as histamine. Therefore, therapeutic 
approaches have attempted to prevent the growth of neurofibro-
mas by stabilizing mast cell activity. Riccardi reported the use of 
antihistamine agent ketotifen (histamine H1-receptor antagonist) 
to hamper the growth of neurofibroma (18) and to reduce tumor-
associated pain and itching (19). Recently, Riccardi reported that 
a patient with NF1 received beneficial responses from long-term 
ketotifen treatment by showing far fewer cutaneous neurofibro-
mas compared with an age-matched control (20). These clinical 
findings further suggested that mast cells could play a support-
ive role in neurofibroma development and mast cell metabolism 
might be a druggable target.
Distinct from other differentiated blood cell types, mast cells 
express the KIT receptor, which is activated by stem cell factor 
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and F). Taken together, these results demonstrated that Schwann 
cells express Scf under both normal and neoplastic conditions, 
and importantly, suggested that Schwann cells could be the in vivo 
source of SCF to mediate mast cell infiltration in neurofibromas.
Tamoxifen-inducible plexiform neurofibroma mouse model. Human 
plexiform neurofibroma has been successfully recapitulated in genet-
ically engineered mouse models with Nf1 ablation in a number of 
Schwann cell–lineage Cre lines, including Krox20-Cre (31), Dhh-Cre 
(32), P0A-Cre (33), and Plp-CreERT2 (34). In this study, we employed 
our recently developed plexiform neurofibroma model with 
Plp-CreERT2 (34) with tamoxifen induction to address the role of 
tumor-derived SCF in neurofibroma development by introducing 
additional Scf depletion into Nf1-ablated Schwann cells.
Myelin-specific proteolipid protein (PLP) is expressed in 
mye linating Schwann cells from the precursor stage and lasts 
throughout their mature stages (35). In the Plp-CreERT2 plexiform 
neurofibroma model, we have previously demonstrated that 
Schwann cells are more susceptible to neurofibroma development 
when Nf1 is ablated during the Schwann cell precursor or imma-
ture Schwann cell stage, but not the mature Schwann cell stage 
(34). Induction of Nf1 ablation at the Schwann cell precursor stage 
(E12–E14) tends to result in a high rate of abortion due to tamoxi-
fen toxicity. Therefore, in this work, we performed induction at 
the immature Schwann cell stage (newborn) to reduce mortality 
caused by induction.
In this study, we treated all newborn pups (both Plp-CreERT2+ 
and Cre– controls) with 4-hydroxytamoxifen to induce Nf1 (and 
Scf) ablation in Schwann cells (Supplemental Figure 1A; supple-
mental material available online with this article; https://doi.
org/10.1172/JCI99424DS1). To validate the appropriateness of 
this new method, we performed a pilot experiment to evaluate 
the induction efficiency of Plp-CreERT2 by using Nf1 genotyping, 
lineage tracing reporter R26-LacZ, and phenotype observation of 
plexiform neurofibroma formation. Nf1 genotyping PCR showed 
a high efficiency of Nf1 ablation (Supplemental Figure 1B). X-gal 
staining revealed a strong LacZ activity in peripheral nervous 
tissues in the DRG and sciatic nerves (Supplemental Figure 1C). 
Most importantly, in a 6-month-old Nf1f/– Plp-CreERT2 mouse, 
multiple plexiform neurofibromas were identified surrounding 
the spinal cord (Supplemental Figure 1D). Taken together, these 
results demonstrated that our 4-hydroxytamoxifen treatment can 
specifically and efficiently induce Cre recombination in Schwann 
cells. This system allows us to address the role of Scf depletion and 
Nf1 heterozygosity in plexiform neurofibroma development.
The contribution of SCF and Nf1 heterozygosity to neurofibroma 
development. Next, we examined the contribution of tumor cell–
derived SCF in neurofibroma genesis by introducing Scf mutation 
on top of Nf1f/– Plp-CreERT2 neurofibroma-bearing mice. We gener-
ated various combinations of Scf transgenes: (a) Scf+/+ (WT), (b) 
Scff/+ (hemizygous deletion in Schwann cells), (c) Scf+/gfp (hemizy-
gous deletion in all cells), and (d) Scff/gfp (homozygous deletion in 
Schwann cells and hemizygous deletion in all other cells). This 
strategy allowed us to achieve a comprehensive comparison in 
order to better delineate the role of SCF in neurofibroma genesis.
In addition, Nf1 heterozygosity has long been considered an 
important supportive factor to sustain the neurofibroma tumor 
microenvironment in Krox20-Cre mouse models (31), likely due to 
(SCF). SCF/KIT signaling drives cell proliferation, migration, and 
survival in selected cell types (21). The action of SCF/KIT signal-
ing has been recognized in the following cellular interactions: 
(a) hematopoietic stem cells (KIT) and endothelial/perivascular 
cells (SCF) (22) (b) melanocyte (KIT) and epithelial keratinocytes 
(SCF) (23), and (c) germ cells (KIT) and surrounding somatic cells 
(SCF) (24). In local tissues, SCF is also a strong chemoattractant 
to induce mast cell chemotaxis from circulating blood into local 
tissues (25). Furthermore, SCF can activate mast cell degranula-
tion to release immunomodulatory molecules (26, 27). There-
fore, identification of the SCF-expressing cells within the tumor 
microenvironment is critical to delineate the mast cell infiltration 
in neurofibroma. A set of in vitro experiments using culture cells 
has shown that Schwann cells express SCF and that their SCF can 
induce mast cell migration (28). Interestingly, mast cell migration 
ability is associated with the Nf1 status in both Schwann cells and 
mast cells; the strongest combination is Nf1–/– Schwann cells with 
Nf1+/– mast cells (28). This synergistic effect was achieved by the 
high SCF expression in Nf1–/– Schwann cells (28) and the Nf1 haplo-
insufficiency in mast cells (29, 30).
In addition to SCF signaling, Nf1 heterozygosity has also been 
considered a critical factor in neurofibroma development. The impor-
tance of Nf1 heterozygosity was first noticed in the pioneer mouse 
plexiform neurofibroma model in which the Nf1f/– Krox20-Cre mice 
developed tumors but the Nf1f/f Krox20-Cre mice (31) did not, high-
lighting the contribution of Nf1+/– to the tumor microenvironment. 
Yang and colleagues further delineated the critical role of Nf1+/– non-
tumor cells from hematopoietic cells by bone marrow transplantation 
experiments (16) and implied Nf1+/– mast cells as critical contributors 
to sustain the neurofibroma microenvironment. Nevertheless, Nf1 
heterozygosity does not seem to be always required in all neurofi-
broma mouse models. For example, Nf1f/f Dhh-Cre mice developed 
plexiform neurofibroma without an Nf1+/– microenvironment (32). 
In this study, by employing new genetic mouse models, we compre-
hensively evaluate the contributions of SCF and Nf1 heterozygosity 
in the neurofibroma tumor microenvironment to better understand 
the roles of these factors in neurofibroma tumorigenesis.
Results
SCF expression in normal and neoplastic Schwann cells in vivo. Mast 
cell infiltration is a pathological feature of neurofibroma; however, 
the source of SCF mediating this mast cell chemotaxis in vivo 
remains unclear. Here, we first took advantage of the new Scfgfp 
transgenic mice (Scf promoter-driven Gfp) (22) to evaluate the 
expression of Scf in normal and neoplastic peripheral nervous tis-
sues. As SCF can be a secreted form of protein, the Scfgfp provides a 
more precise identification of SCF-expressing cells compared with 
conventional SCF immunostaining. We observed SCF-expressing 
cells in normal peripheral nervous tissues in both dorsal root ganglia 
(DRG) and sciatic nerves (Figure 1, A and B). Immunostaining of 
S100β (a marker for both myelinating and nonmyelinating Schwann 
cells) confirmed that the SCF-expressing cells were Schwann cells in 
these normal peripheral nervous tissues (Figure 1, C and D). Next, 
we introduced Scfgfp into a previously established plexiform neuro-
fibroma genetically engineered mouse model (31) to determine the 
Scf expression in neurofibromas. We found that Scf expression was 
strongly detected in the plexiform neurofibroma tumor (Figure 1, E 
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2D) mice. These comparisons allowed us to determine the contri-
bution of Nf1 heterozygosity and tumor-derived SCF in the neuro-
fibroma tumor microenvironment.
First, we evaluated the disease progression by comparing the 
tumor-bearing Plp-CreERT2 mice with Cre– controls. In all groups 
with identical Nf1 and Scf status, the survival rates of Plp-CreERT2 
mice are significantly shorter than those of Cre– controls (Figure 
2A), confirming the tumor burden in neurofibroma-bearing Plp-
CreERT2 mice (34, 36).
Second, we addressed the role of Nf1 heterozygosity by com-
paring the disease progression between Nf1f/– and Nf1f/f background 
mice.  We found that both Nf1f/– Plp-CreERT2 and Nf1f/f Plp-CreERT2 with 
paired Scf status mice succumbed to neurofibroma development 
(Figure 2A). However, mice in the Nf1f/– group died from tumor 
development much faster than those in the Nf1f/f group (Figure 2B). 
These findings revealed that Nf1 heterozygosity is not absolutely 
required for neurofibroma development. However, inclusion of Nf1 
heterozygosity in nontumor cells significantly enhanced neurofi-
broma progression, suggesting that germline Nf1 heterozygosity is 
the contribution from Nf1+/– cells in the tumor microenvironment, 
especially mast cells (16). However, the requirement of the Nf1+/– 
microenvironment was not fully recapitulated in another neuro-
fibroma model system by using Dhh-Cre (32), suggesting that Nf1 
haploinsufficiency might contribute to neurofibroma development 
in a context-dependent manner. Therefore, we also reevaluated 
the contribution of Nf1 heterozygosity by comparing the tumor pro-
gression between Nf1f/f and Nf1f/– mice with Plp-CreERT2.
In this study, we designed a comprehensive mouse breeding 
strategy that allowed us to examine the contribution of SCF and Nf1 
heterozygosity in neurofibroma development (Supplemental Fig-
ure 2A). A cohort size of 213 mice from 8 potential neurofibroma-
bearing genotypes was enrolled in the survival study (Table 1). We 
also included a cohort of mice that do not carry Cre as controls. We 
employed Kaplan-Meier survival analyses to determine the tumor 
progression and death secondary to tumor burden among (a) Plp-
CreERT2 (tumor-bearing) and Cre– (no tumor) (Supplemental Figure 
2B), (b) Nf1f/– and Nf1f/f background (Supplemental Figure 2C), and 
(c) Scf+/+, Scff/+, Scf+/gfp, and Scff/gfp background (Supplemental Figure 
Figure 1. Scf expression in normal nervous tissues and neurofibroma tumors. (A) Scfgfp identified Scf expression in DRG. (B) Scfgfp identified Scf expres-
sion in sciatic nerve. (C) Scf expression in S100β+ Schwann cells in DRG. (D) Scf expression in S100β+ Schwann cells in sciatic nerves. (E) Scfgfp identified Scf 
expression in DRG with spontaneous plexiform neurofibroma. (F) GFP immunohistochemical staining identified Scf-expressing cells (by Scfgfp) in plexiform 
neurofibroma tumor tissue. Scale bar, 500 μm in A, B, and E. Scale bar, 100 μm in C, D, and F.
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general, these tumors were found at highest frequency in the cer-
vical region (115 of 116 extracted spinal cords) and in the thoracic 
nerves (91 of 116 extracted spinal cords), but were less common in 
the cauda equine (39 of 116 extracted spinal cords). This trend of 
tumor preference applied to all groups and was not dependent on 
particular genotypes.
Although plexiform neurofibroma can develop in mice with 
various Scf and Nf1 statuses, we were interested in understanding 
whether these genetic alternations would affect the pathological 
features of neurofibroma. Therefore, we performed analyses to 
evaluate neurofibroma derived from different genotypes. First, 
we characterized these tumors by H&E staining. We found that 
tumors from all groups shared classical pathological features of 
neurofibroma, including cellular disorganization with wavy nuclei, 
and high collagen content (Figure 3B). Second, we performed 
immunostaining for S100β, which is a common diagnostic marker 
for neurofibroma. Our results showed that S100β+ Schwann cells 
were exhibited in a similar density and morphology among all 
groups (Figure 3C). Third, we quantified the tumor burden in each 
group. As mentioned previously, mouse plexiform neurofibromas 
were preferentially developed in cervical nerves. We therefore 
graded the tumor burden of cervical plexiform neurofibromas by 
their severity and prevalence in this region. In a total of 116 spi-
nal cords, we found that the tumor burden was not statistically 
different between any 2 groups (Figure 3D). In summary, we did 
not notice any difference in plexiform neurofibroma histological 
structure due to the alterations of Scf and Nf1 status in this study.
Schwann cells are the primary source of SCF for mast cell infil-
tration in neurofibromas. The key rationale behind our approach 
to deplete SCF in neurofibroma Schwann cells was to evaluate 
the impact of mast cells in the neurofibroma tumor microenviron-
ment. Although we only observed a small difference in tumor pro-
gression by deleting Schwann cell–derived SCF, we reasoned it is 
necessary to quantify mast cell infiltration in these tumors.
Therefore, we compared the level of mast cell infiltration in 
neurofibroma tumor tissues with various Scf statuses by toluidine 
blue staining. We found that mouse neurofibroma tumors with 
normal Scf expression showed high levels of mast cell infiltration 
(Figure 4A), in line with the human neurofibroma pathological 
signatures (11–14). Strikingly, we found that mast cell density in 
neurofibroma is correlated to SCF expression in Schwann cells. 
Heterozygous loss of Scf (Scff/+ or Scf+/gfp) lead to a partial decrease 
of mast cells (Figure 4B). On the other hand, complete loss of Scf 
(Scff/gfp) in Schwann cells resulted in a remarkable reduction of 
mast cells in tumors (Figure 4B). We found similar results in both 
Nf1f/f and Nf1f/– backgrounds (Figure 4B). Importantly, we found 
that in the case of hemizygous Scf loss (Scf+/gfp), the reduction of 
mast cells was more drastic in Nf1f/f tumors than in Nf1f/– tumors. 
We reasoned that this could be due to hyperproliferation of the 
Nf1 haploinsufficient mast cells as previously reported (29, 30). In 
brief, these results demonstrate that SCF from neoplastic Schwann 
cells is the key chemoattractant to drive mast cell chemotaxis in 
neurofibroma. However, removal of this source of SCF and mast 
cells was not sufficient to relieve tumor burden (Figure 3).
Neurofibroma is associated with high levels of macrophage infil-
tration regardless of SCF status. The observation that neurofib-
roma progression was only slightly affected when mast cells were 
a modifying factor for neurofibroma development and explaining 
the differential observations in previous reports (31, 32).
Finally, we determined the contribution of tumor-derived 
SCF in neurofibroma development. We compared the neurofi-
broma progression between various Scf statuses in tumor cells. 
In the common background of Nf1f/– Plp-CreERT2, we found that Scf 
knockout (Scff/gfp) slightly prolonged the survival of mice; however, 
the difference only reached statistical significance when com-
pared with Scf+/gfp (P = 0.0191), not to Scff/+ (P = 0.0768) or Scf+/+ 
(P = 0.1852). In the common background of Nf1f/f Plp-CreERT2, we 
found that Scf knockout (Scff/gfp) did not affect the survival of mice 
as compared with Scf+/gfp (P = 0.5665), Scff/+ (P = 0.1924), or Scf+/+ 
(P = 0.9817). In short, these results reveal that depletion of SCF in 
neurofibroma Schwann cells only slightly influences its progres-
sion, suggesting the existence of other contributors to the neurofi-
broma tumor microenvironment. In addition, recent studies have 
shown that estrogen from females correlates with the prevalence 
of optic glioma (37, 38). Therefore, in this study, we also utilized 
our survival data set (Table 1) to compare the progression of neu-
rofibromas between male and female mice, and we did not notice 
any significant difference (Supplemental Figure 3).
Loss of SCF does not affect neurofibroma anatomy or histopa-
thology. To comprehensively analyze all of the developed tumors 
in the peripheral nervous tissues, we performed whole spinal cord 
extraction to identify paraspinal plexiform neurofibromas. We 
also included the Rosa26-LacZ lineage tracing reporter to mark 
Schwann cells. Therefore, after whole-mount X-gal staining, the 
plexiform neurofibroma tumors could be highlighted, providing 
an advantage for the clear identification of tumor locations and 
sizes. We performed the analyses for all 8 potential tumor-bearing 
groups (Table 1). To our knowledge, this is the first mouse plexi-
form neurofibroma study using whole spinal cord extraction in 
combination with X-gal staining enhancement as readout to quan-
tify tumor burden.
Our results showed that plexiform neurofibromas can be found 
in every mouse among 8 potential tumor-bearing groups (Figure 
3A), which is in agreement with our previous results showing all 
tumor-bearing groups had shortened survival due to tumor burden 
(Figure 2A). Based on their anatomical locations, these tumors can 
be classified into 3 groups: cervical, thoracic, and cauda equine. In 
Table 1. The genotypes and number of mice enrolled in the 
plexiform neurofibroma study
Mouse n
Nf1f/– Scf+/+ Plp-CreERT2 21
Nf1f/– Scff/+ Plp-CreERT2 28
Nf1f/– Scf+/gfp Plp-CreERT2 30
Nf1f/– Scff/gfp Plp-CreERT2 24
Nf1f/f Scf+/+ Plp-CreERT2 33
Nf1f/f Scff/+ Plp-CreERT2 30
Nf1f/f Scf+/gfp Plp-CreERT2 19
Nf1f/f Scff/gfp Plp-CreERT2 28
Total 213
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suggested that targeting mast cells alone is not potent enough to 
efficiently relieve neurofibroma burden, suggesting the existence 
of additional mediators in the neurofibroma microenvironment. 
Therefore, we evaluated other inflammatory signatures in these 
neurofibroma tumors. Macrophage is another type of inflamma-
tory cell found in neurofibroma (40, 41). Similar to mast cells, 
removed from the tumor microenvironment suggested that mast 
cells are a modifier rather than a driver in neurofibroma develop-
ment (Figure 2C). This is in alignment with the human clinical 
findings that only a portion of plexiform neurofibromas in patients 
with NF1 showed partial response to KIT inhibitor imatinib mesyl-
ate (39). The results from both preclinical and clinical studies 
Figure 2. Contributions of Nf1 heterozygosity and SCF to neurofibroma progression. The speed of neurofibroma progression was determined by the survival 
of mice. (A) Survival comparison between neurofibroma-bearing (PlpCreERT2) and tumor-free (no Cre) mice. (B) Survival comparison between neurofibroma-
bearing mice with germline homozygous Nf1 (Nf1+/+) and heterozygous Nf1 (Nf1+/–) status. (C) Survival comparison between neurofibroma-bearing mice with 
the following variable Scf status: (1) Scf+/+, WT; (2) Scff/+, hemizygous deletion in Schwann cells; (3) Scf+/gfp, hemizygous deletion in all cells; and (4) Scff/gfp, 
homozygous deletion in Schwann cells and hemizygous deletion in all other cells. The number of mice in each group ranged from 19–30 as labeled in each indi-
vidual figure. The statistics were performed by Kaplan-Meier estimator with log-rank test. In this figure, the same survival curves from Nf1f/– Scf f/gfp Plp-CreERT2 
and Nf1f/f Scf f/gfp Plp-CreERT2 double knockout mice were presented in A–C to compare the survival between different genotype cohorts.
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macrophages are recruited to neurofibroma by tumor-derived 
chemoattractant macrophage CSF1 (40).
We therefore determined macrophage density by staining with 
macrophage marker Iba1 (40). We found that macrophages were 
present at high densities in neurofibroma tumors in all groups; 
these cells are diffused across the entire tumor region (Figure 5A). 
Macrophages can polarize into different subtypes of cells depend-
ing on the context of the microenvironment (42). Therefore, we 
further phenotyped these macrophages using markers for M1 
(proinflammatory) and M2 (protumorigenic) macrophages. Our 
Figure 3. Contributions of Nf1 heterozygosity and SCF to neurofibroma development. (A) The structure of whole spinal cord from neurofibroma-nearing 
mice. X-gal staining marks Plp-lineage Schwann cells. Plexiform neurofibromas were highlighted as enlarged DRGs. A representative image in each group 
was selected from a 10- to 12-month-old mouse as shown in Supplemental Figures 4–11. (B) The histology of cervical plexiform neurofibromas. (C) S100β 
immunohistochemical staining for Schwann cells in the tumors and nontumor nerves. (D) Quantification of the severity of plexiform neurofibroma by a 
reference grading scale in the left panel. No statistically significant difference was identified by comparing any 2 groups. Cervical tumors in left panel are 
representative images for each level (0–5) selected from 116 whole spinal cords as shown in Supplemental Figures 4–11. For A–C, representative images 
were compared from mice at similar ages (10–12 months) in each group. Statistics were performed by 1-way ANOVA. Data are mean ± SEM. Scale bar, 1 cm 
in A. Scale bar, 100 μm in B and C.
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results showed that macrophages in neurofibromas are predomi-
nantly iNOS+ M1 macrophages (Figure 5B) rather than mannose 
receptor+ M2 macrophages (Supplemental Figure 12), suggesting 
an inflammatory status in neurofibromas. We also noticed the 
presence of a small number of CD3+ T lymphocyte clusters in the 
tumors (Supplemental Figure 13). Unlike macrophages, however, 
T lymphocytes in neurofibromas were in groups and at a much 
lower density. In contrast to the tumor areas, our data showed that 
only a small number of M1 macrophages are detected in nearby 
nontumor nerves (Figure 5), suggesting a correlation between 
inflammation and neurofibroma formation. Furthermore, we also 
found that macrophage levels were not affected by the alterna-
tions of Scf or Nf1 heterozygosity status (Figure 5). This finding 
partly explains the limited efficacy of our antitumor approach by 
removing SCF and mast cells (Figures 2 and 3).
Paraspinal plexiform neurofibroma preferentially developed at 
cervical and thoracic T5–T8 nerves. In our whole spinal cord extrac-
tion analysis in a cohort of 116 mice, we found that paraspinal 
plexiform neurofibromas were most prevalent in cervical nerves 
(Figure 3A, Supplemental Figures 4–11, and Supplemental Table 1). 
Plexiform neurofibromas can also be found in thoracic nerves and 
in the cauda equina, but in much lower frequencies (Figure 3A, 
Supplemental Figures 4–11, and Supplemental Table 1). After ana-
lyzing the thoracic neurofibromas in 116 spinal cords, we noticed 
that among 13 pairs of thoracic nerves, plexiform neurofibromas 
appeared to preferentially develop in particular areas. We there-
fore performed quantification analysis to determine the number 
and sizes of tumors formed in each thoracic nerve.
We found that all 8 different groups of tumor-bearing mice 
gave rise to a similar trend of thoracic neurofibroma formation 
(Figure 6 and Supplemental Figure 14). This pattern can be sum-
marized as follows (a) among 13 pairs of thoracic nerves, tumors 
only develop from T1 to T9, no tumors were from T10 to T13 
(Figure 6), (b) tumors with the largest average size were located 
at T5 to T8 (Figure 6), and (c) in a total of 188 thoracic tumors, 
tumors were most frequently identified in T7 (40%), and the T5–
T8 tumors take up 69% prevalence in all thoracic tumors (Supple-
mental Figure 14).
Taken together, these results indicate that the cervical nerves 
and the thoracic nerves at T5–T8 are the “hot zones” for paraspi-
Figure 4. Mast cells in the neurofibroma tumor 
microenvironment. (A) Mast cells (arrows) in 
neurofibromas were identified by toluidine blue 
staining. Results were representative images 
compared with mice at similar ages (10–12 
months) in each group. (B) Statistic analysis of 
mast cell density in neurofibroma. Statistics 
were performed by 1-way ANOVA. Significant 
differences were noted by asterisks: *P < 0.05, 
**P < 0.01, and ****P < 0.0001. Data are mean ± 
SEM. Scale bar, 100 μm.
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Figure 5. Mac-
rophages in the 
neurofibroma tumor 
microenvironment. 
Iba1 (A) and iNOS 
(B) immunohisto-
chemical staining for 
macrophages in the 
cervical plexiform 
neurofibroma tumor 
and nearby nontumor 
nerve regions. Note 
the density difference 
of positive cells in 
tumors and nerves. 
Representative 
images are shown 
from mice with similar 
ages (10–12 months) 
in each group (n = 3). 
Scale bars, 100 μm.
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nal plexiform neurofibroma formation. Inter-
estingly, in mice, the cervical vertebras and 
the T5–T8 vertebra, which are located in the 
middle of the thoracic spine, flex and extend 
more than any other part of the spine. There-
fore, we speculate that these nerves and DRGs 
may be more prone to injury, which might be 
related to the observations of M1 macrophages 
and T lymphocytes in neurofibromas (Figure 5 
and Supplemental Figure 13).
Tumorous Schwann cell–derived SCF is dis-
pensable for neurofibroma development in the 
transplant tumor model. In our genetically 
engineered mouse models, we showed that 
SCF expression in tumorous Schwann cells 
is not absolutely required for neurofibroma 
development (Figures 2 and 3). Although we 
have shown effective tamoxifen induction 
efficiency by genotyping and X-gal staining 
(Supplemental Figure 1), we still cannot rule 
out the possibility that there were a small por-
tion of Scffl alleles in Schwann cells that were 
not completely ablated due to the efficacy lim-
itation of the Cre/Flox recombination system.
We therefore employed another neurofi-
broma model we established previously (43). 
That system utilizes Nf1-ablated skin-derived 
precursors (SKPs) as the cell of origin for neu-
rofibroma in nude mice orthotopic allograft 
transplantation, where the Nf1-ablated SKPs 
develop into bona fide neurofibroma when 
transplanted into sciatic nerves. In the pres-
ent study, we took advantage of that system to 
address the role of tumorous SCF in neurofi-
broma development by examining the tumori-
genicity of Nf1Δf/Δf Scfgfp/gfp (Nf1/Scf-DKO) SKPs. 
The Scfgfp allele is functionally equivalent to Scf 
straight knockout; therefore, biallelic Scfgfp con-
fers an absolute loss of SCF (22).
We first examined the Scf expression in 
SKPs by taking advantage of Scfgfp as a reporter. 
We found that SKP spheres express Scf (Figure 
7A). To ensure this SCF expression was in the 
neural crest–derived stem cells in the SKPs, we 
stained neural crest marker Nestin and found 
that Nestin+ cells were colocalized with GFP 
in monolayered SKP cells (Figure 7B). Next, 
we generated SKPs from mice with the follow-
ing 3 genotypes: (a) Nf1f/f Scf+/+, (b) Nf1f/f Scf+/gfp, 
Figure 6. The prevalence of thoracic neurofibroma 
in different thoracic nerves. The number and sizes of 
thoracic neurofibromas in different thoracic locations 
in different groups of neurofibroma-bearing mice. 
Figure represents the sizes and locations of each 
tumor with means. Note the high tumor prevalence 
in T5–T8 (n = 7–18 mice per group).
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tumorigenicity due to the lack of SCF expression in the neoplas-
tic Schwann cells. We also included Nf1Δf/Δf Scf+/gfp SKPs as a par-
tial SCF loss control. We found that SKPs from all 3 groups gave 
rise to neurofibromas with similar sizes (Figure 7E). Histologi-
cally, neurofibromas derived from all groups showed similar tis-
sue structure (Figure 7F). However, the levels of infiltrated mast 
cell density in neurofibromas were strongly correlated to the Scf 
status in the transplanted SKP, where the Nf1Δf/Δf Scf+/+ tumor had 
and (c) Nf1f/f Scfgfp/gfp. We then infected these SKPs by adenovirus- 
carrying Cre recombinase (Ad-CMV-Cre) to ablate their Nf1 
alleles and obtain the following SKPs: (a) Nf1Δf/Δf Scf+/+ (Nf1-KO), (b) 
Nf1Δf/Δf Scf+/gfp, and (c) Nf1Δf/Δf Scfgfp/gfp (Nf1/Scf-DKO) (Figure 7C). 
These SKPs were transplanted into the sciatic nerves in nude mice 
and harvested 5 months after transplantation (Figure 7D).
The rationale of this experiment was to determine whether 
Nf1/Scf-DKO and Nf1-KO will show different neurofibroma 
Figure 7. Contribution of tumor-derived 
SCF in SKP transplantation neurofibroma 
model. (A) Scfgfp reporter identified Scf 
expression in the SKP spheres. (B) Scf 
expression (determined by Scfgfp) in the 
Nestin+ neural crestlike stem cells in the 
SKPs. (C) The strategy of generation of 
Nf1/Scf DKO SKPs and controls. (D) Illustra-
tion of SKP transplantation in sciatic 
nerves in nude mice for neurofibroma 
development. (E) The observation of 
sciatic nerves with LacZ staining (marked 
by dark blue color) after SKP transplanta-
tion. (F) The histology of sciatic nerves at 
low magnification (×40, upper panel) and 
high magnification (×400, lower panel). (G) 
Toluidine blue staining for mast cells. In 
E–G, results were representative from 5–9 
tumors, as labeled. Scale bars, 100 μm in A, 
F, and G. Scale bar, 50 μm in B.
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genesis, all Nf1-ablated Schwann cells should harbor the same 
chance to form tumors, and therefore tumors should develop in a 
homogenous manner in all peripheral nerves under the efficient 
induction condition that we have achieved (Supplemental Figure 1). 
However, our results clearly demonstrate the preferential sites for 
plexiform neurofibroma in the cervical nerves and in the thoracic 
T5–T8 nerves, pointing to the requirement of other factors, whether 
intrinsic or extrinsic, in addition to Nf1 loss for neurofibroma 
development (Figure 8).
In mice, the joints in cervical vertebras and in the mid-thoracic 
vertebras are most flexible to allow head rotation and walking. 
Therefore, their associated nerves and DRGs may be more prone to 
injury, leading to higher neurofibroma prevalence, as nerve injury 
has been associated with neurofibroma development (44, 45). Our 
observation that cervical nerves serve as a “hot zone” for plexiform 
neurofibroma in this mouse model appears to mimic similar obser-
vations in human NF1 studies (46, 47). We hypothesize that physical 
motion could lead to minor but repetitive nerve injuries surround-
ing these vertebras compared with the nerves near other less-active 
spinal vertebras. Tissue injuries are usually accompanied by inflam-
mation as a mechanism for tissue repair. Repetitive inflammation 
has been generally recognized as a stimulating factor for neoplasia, 
primarily due to the reactive oxygen species–induced DNA muta-
tions and the high concentrations of cytokines and growth factors 
from infiltrating inflammatory cells (Figure 8) (48, 49).
In addition to mast cells, macrophages are another type of 
inflammatory cell frequently found in neurofibromas. Macro-
the highest level, Nf1Δf/Δf Scf+/gfp tumor had the moderate level, 
and Nf1Δf/Δf Scfgfp/gfp tumor had the lowest level (Figure 7G). This 
finding confirmed that mast cell infiltration in neurofibroma in 
vivo is primarily dependent on the SCF expression from tumor-
ous Schwann cells; however, the differences in mast cell infiltra-
tion do not alter neurofibroma tumorigenesis. These results are 
in agreement with our previous mouse model experiments pre-
sented earlier (Figures 2–4).
Discussion
Neurofibroma is a benign peripheral nerve sheath tumor that can 
cause severe disfiguring in a majority of patients with NF1. Fighting 
neurofibroma has been a continuous effort with limited success. 
In this study, we aimed to understand the important interactions 
between tumorous Schwann cells and their microenvironmental 
cells by employing new genetically engineered mouse models. 
We found that (a) tumorous Schwann cells are the primary source 
of SCF that mediates mast cell chemotaxis in neurofibroma but 
that mast cell density does not correlate with tumor burden, (b) 
paraspinal neurofibroma initiation appears to be more prevalent 
in certain areas of the spine that are prone to nerve injury, such as 
the cervical or T5–T8 DRGs, and (c) Nf1 heterozygosity plays a key 
role in tumorigenesis, whereas it is not absolutely required for but 
can modify neurofibroma tumorigenesis.
It is widely recognized that biallelic Nf1 loss is the key funda-
mental requirement for neurofibroma initiation (2–7). If biallelic 
Nf1 loss is the only requirement to initiate neurofibroma tumori-
Figure 8. Hypothetical model of neurofibroma initiation 
and tumorigenesis. Neurofibroma occurs more commonly 
at injury-prone nerves. Nerve injury induces inflamma-
tion as a mechanism of tissue repair. Nerve inflamma-
tion results in the infiltration of inflammatory cells and 
high concentrations of reactive oxygen species (ROS) and 
growth factors. NF1 mutant Schwann cells may interplay 
with the inflammatory microenvironment that contributes 
to neurofibroma tumorigenesis. Tumorous Schwann cells 
express chemokines and cytokines, such as SCF and CSF1, 
to recruit inflammatory cells, including mast cells and 
macrophages. This model may explain the presence of 
mast cells and macrophages in the neurofibroma tumor 
microenvironment, the high neurofibroma frequency in 
injury-prone nerves, and our observation that removal of 
mast cells alone is not sufficient to relieve tumor burden.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
2 8 5 9jci.org   Volume 128   Number 7   July 2018
lineage tracing reporter was obtained from The Jackson Laboratory 
and included in all the mice in this study. Mice were maintained on 
a 129/SvEv and C57BL/6 mixed background. Male and female mice 
were nonselectively included in this study. The genotype and age of 
mice were indicated in each experiment.
4-hydroxytamoxifen induction. The Plp-CreERT2 is a tamoxifen 
inducible Cre system. In order to induce Cre recombinase expres-
sion in the Plp-lineage Schwann cells in mice, we injected 40 μg of 
4-hydroxytamoxifen subcutaneously into each P0–P2 pup. Efficient 
induction was validated in Supplemental Figure 1.
Plexiform neurofibroma progression analysis. In this study, all the 
mice were subjected to the same dose of 4-hydroxytamoxifen induc-
tion at the same stage of age. Therefore, we assumed that the initia-
tion and progression of spontaneous plexiform neurofibroma in each 
individual neurofibroma-bearing mouse shared the same probability; 
the only variable is their genotype. Mice with benign plexiform neuro-
fibroma are generally asymptomatic during their early life. Along the 
tumor progression, the enlarged tumors could compress the DRG and 
spinal cord, leading to impaired peripheral and central nervous sig-
naling. In the end stage of disease development, mice are commonly 
skinny and present with limpness, hunched back, rough coat, and shal-
low breathing. When mice were reported sick by the Animal Research 
Center, we euthanized them and extracted the entire spinal cord for 
histology analysis. The date of euthanasia was documented for the 
length of survival. Some mice died before we could perform dissec-
tion. Their dates of death were also documented for survival analy-
sis; however, their tissues were excluded from our histology analyses 
for quality purposes. Overall, mice with plexiform neurofibroma live 
about 6 to 18 months of age. Mouse survival analysis was compared by 
Kaplan-Meier statistics.
Whole spinal cord extraction. Mice were anesthetized by intra-
peritoneal injection of a mixture of 30 mg/ml ketamine and 4 mg/ml 
xylazine solution at a dose of 100 μl per 25 g. Total body perfusion was 
performed by transcardial injection of 20 ml PBS and then 20 ml of 4% 
paraformaldehyde. The vertebras with connecting dorsal ribs, pelvis, 
and femurs were excised. The extraction of spinal cord and connect-
ing peripheral nerves was performed by carefully dissecting out the 
muscles and bones under a dissection microscope.
LacZ staining. When the whole spinal cord was extracted, it was 
briefly fixed in 4% paraformaldehyde for 30 minutes followed by rins-
ing in PBS. LacZ staining on the spinal cord was performed in X-gal 
solution (1 mg/ml 4-chloro-5-bromo-3-indolyl-β-galactoside, 4 mM 
potassium ferrocyanide, 4 mM potassium ferricyanide, 2 mM magne-
sium chloride in PBS) at 37°C for overnight. X-gal–stained spinal cord 
was fixed in 10% formalin overnight and then imaged.
Plexiform neurofibroma quantification. For cervical neurofibromas, 
the tumors tend to present in a diffuse pattern due to the tight prox-
imity of cervical nerves. Therefore, it was difficult to grade the size 
of independent tumor in this region. To overcome this difficulty, we 
established a tumor burden scale (Figure 3D) to quantify the relative 
severity and prevalence of cervical neurofibroma in each mouse, as fol-
lows: level 0, no tumor was detected; level 1, tumors formed in less than 
20% of cervical nerves; level 2, tumors formed in 20%–40% of cervical 
nerves; level 3, tumors formed in 40%–60% of cervical nerves; level 4, 
tumors formed in 60%–80% of cervical nerves; level 5, tumors formed 
in more than 80% of cervical nerves. Data represent the averages of 3 
independent blind-grading experiments performed by different neuro-
phages can polarize into different types of cells depending on the 
context of environmental cues (42). M1 macrophages are phago-
cytic and they are often present in inflammatory tissue to remove 
the damaged cells. On the other hand, M2 macrophages are pro-
tumorigenic; they are associated with the hyperproliferation of 
neoplastic cells. A recent genomic profiling revealed that macro-
phages in neurofibromas showed stronger M1 signatures than M2 
(41). This finding is in agreement with our discovery and suggests 
a continuous inflammation in the neurofibroma microenviron-
ment. Taken together with our discovery that cervical nerves and 
the thoracic T5–T8 nerves are the hot spots for neurofibromas, it 
would be important to understand through future studies whether 
this macrophage infiltration is associated with nerve injury.
If nerve injury is a modifying factor for neurofibroma initia-
tion in addition to Nf1 loss, the presence of mast cells in neu-
rofibromas might be one of the many inflammatory cell infil-
trations (including macrophages and others) that accompany 
nerve injury, whether mechanical or molecular, explaining the 
limited efficacy in the attempt to reduce mast cell infiltration 
to prevent neurofibroma development in this study (Figures 2 
and 3). Therefore, future clinical trials utilizing dual inhibitions 
for both mast cells and macrophages may be much more effec-
tive for this tumor. On the other hand, although we found that 
mast cell infiltration in neurofibromas was markedly diminished 
when SCF was depleted in Schwann cells, it is also possible that 
the mast cell number did not fall below a required threshold level 
to prevent tumor development. Thus, Schwann cell SCF may be 
a crucial but not the only source of SCF for recruiting mast cells, 
suggesting the contribution of SCF from other cell types in the 
neurofibroma tumor microenvironment. This might be why tar-
geting the KIT receptor on mast cells, whether via genetic abla-
tion or pharmacological inhibition with imatinib, is effective in 
preventing neurofibroma development (16, 39). Future experi-
ments to utilize mice with mast cell–, fibroblast-, or endothelial 
cell–specific Cre to explore the role of SCF from other cell types 
in the neurofibroma microenvironment would help to delineate 
the absolute requirement of SCF within the neurofibroma micro-
environment for tumor initiation.
In summary, our study highlighted the contribution of inflam-
mation (possibly due to nerve injury) in neurofibroma initiation (Fig-
ure 8). Here we propose that prevention of repetitive nerve injury 
(both physiological and traumatic) or blocking of nerve inflamma-
tion could be a new strategy to manage neurofibroma growth. This 
concept is partly supported by the preliminary success of long-term 
treatment of ketotifen in a human (20), as it is not only in possession 
of antihistamine from mast cells but also antiinflammatory activi-
ties (50). Another similar success in mouse models was achieved by 
treatment with PLX3397 (40), a dual inhibitor of KIT and CSF1R, 
which could simultaneously block mast cells and macrophages. 
Thus, the findings in our study address the contributions of tumor-
derived SCF, inflammation, and germline Nf1 heterozygosity to neu-
rofibroma development and provide insights for the design of future 
neurofibroma therapies in targeting its tumor microenvironment.
Methods
Mice. The Nf1fl (51), Nf1– (52), Scffl (22), Scfgfp (22), and Plp-CreERT2 (53) 
mice have been reported in previous literatures. The Rosa26-LacZ (54) 
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media every 3 to 4 days and passaged every 7 days. Ablation of Nf1 was 
performed by Ad-CMV-Cre infection as previously described (36).
SKP transplantation in nude mice. Athymic nude mice were anes-
thetized as described above. Dissociated SKP single cells (5 × 105) were 
resuspended in 40 μl of L15 medium (Gibco) and then injected into 
the sciatic nerve in athymic nude (nu/nu) mice as previously described 
(36). Neurofibromas derived from SKPs were harvested 5 months after 
SKP transplantation.
Statistics. All statistical analyses in this study were performed 
using Prism7 (GraphPad). For mouse survival analysis, the Kaplan-
Meier estimator with log-rank statistical test was employed. Multiple 
group comparison was performed by 1-way ANOVA test. Data are 
mean ± SEM. Significant differences are noted by asterisks: *P < 0.05, 
**P < 0.01, ***P < 0.001, and ****P < 0.0001.
Study approval. Mouse care and use in this study were approved by 
the IACUC at the University of Texas Southwestern Medical Center. 
The approved protocol numbers are 2011-0156 and 2017-102108.
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fibroma research scientists. For thoracic neurofibromas, we identified 
the tumors by the size of DRG, which is equal or greater than 1 mm × 1 
mm. The volume of each tumor was calculated by the formula (length) 
× (width)2 × 0.5.
Histology analysis. For histology analysis, visible plexiform neuro-
fibroma was excised from the spinal cord and then subjected to tis-
sue processing and paraffin embedding. Tissue block was sectioned at 
5-μm thickness. H&E staining was performed according to the manu-
facturer’s protocol (StatLab).
Immunostaining. Immunostaining was performed on paraffin 
sections after deparaffinization, rehydration, and antigen retrieval. 
The primary antibodies used in this study were S100β (Dako, Z0311), 
GFP (Aves, 1020), Iba1 (Wako, 019-19741), iNOS (Abcam, ab15323), 
mannose receptor (Abcam, ab64693), CD3 (Abcam, ab16669), and 
Nestin (Abcam, ab24692). For immunofluorescent staining, the 
primary antibodies were detected by secondary antibodies conju-
gated with Cy3 (Jackson ImmunoResearch), and nuclei were counter-
stained with DAPI (Vector Laboratories). For immunohistochemical 
staining, the primary antibodies were detected by biotin-conjugated 
secondary antibodies followed by streptavidin conjugated with DAB 
(Vector Laboratories).
Toluidine blue staining. Toluidine blue staining for mast cells was 
performed on paraffin sections after deparaffinization and rehydra-
tion. Tissue was stained with 0.5% toluidine blue solution (Acros 
Organics) for 5 minutes and rinsed by water. Then tissue was dehy-
drated in increasing concentrations of ethanol solutions and xylene 
before mounting. This dye highlights mast cells in purple, whereas 
other cells were in blue.
SKP isolation and Nf1 ablation by adenoviral Cre. SKP isolation was 
described previously (55). Briefly, dorsal skin was excised from P0–P2 
neonatal mouse pups followed by the removal of adipose and muscle 
tissues. The skin was rinsed by HBSS (Invitrogen) and then chopped to 2 
mm to 3 mm in size by sterile technique. To isolate single cells from the 
skin, tissue was gently shaken in 0.5% collagenase I (Invitrogen) at 37°C 
for 1 hour. Tissue underwent pipetting several times to facilitate tissue 
dissociation. Undissociated tissue was removed by 70-μm cell strainer. 
Cells in suspension were pelleted and then washed with serum-free 
DMEM/F12 media (Invitrogen). Skin cells were plated at a density of 20 
cells/μl on ultra-low attachment plates (Corning) in SKP proliferation 
media (DMEM/F12 containing penicillin/streptomycin [0.1%], fungi-
zone [40 μg/ml], B27 [without vitamin A], epidermal growth factor [20 
ng/ml], and basic fibroblast growth factor [40 ng/ml]) (Sigma-Aldrich). 
SKPs formed spheres by the time of culture. SKPs were fed by fresh 
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